Ginkgo biloba

Within the SIRIAM Platform, Ginkgo biloba Leaf Extract functions as one of the principal botanical components of the Release Core.

Unlike the Structural & Dermal Support Core ingredients, which establish the pharmaceutical architecture of the formulation, Ginkgo biloba contributes to the functional identity of the Release phase through its well-characterised botanical profile.

Within the SIRIAM formulation philosophy, Ginkgo biloba is not incorporated to establish regional anatomical identity. Rather, it serves as a common Release Core ingredient that complements other botanical and functional components, including Palmitoylethanolamide (PEA), Boswellia serrata, Ruta graveolens and Arnica montana.

Its inclusion reflects the platform philosophy of integrating botanicals with a scientifically plausible biological rationale into a standardized pharmaceutical vehicle while recognising that the SIRIAM neurodermal architecture represents a novel formulation concept.

Ginkgo biloba is one of the most extensively investigated medicinal plants in modern phytotherapy. Standardised leaf extracts contain two principal classes of bioactive constituents:

Flavonoid glycosides, which possess antioxidant properties.

Terpene lactones (including ginkgolides A, B, C and bilobalide), which have been studied for their biological effects on vascular physiology, cellular metabolism and neuroinflammatory signalling.

Experimental studies demonstrate multiple biological mechanisms, including:

modulation of oxidative stress;

effects on endothelial function;

influence on microvascular physiology;

modulation of inflammatory mediators;

effects on mitochondrial function;

experimental neuroprotective activity in laboratory models.

Human clinical research has primarily focused on oral standardised Ginkgo extracts, particularly in cognitive impairment, dementia, peripheral arterial disease and tinnitus. Although results vary according to indication, numerous systematic reviews support a favourable safety profile and modest clinical benefits in selected populations.

Evidence supporting topical Ginkgo formulations remains comparatively limited. Experimental studies suggest antioxidant and microcirculatory effects in the skin, but high-quality clinical investigations are scarce.

Current scientific evidence evaluates Ginkgo biloba primarily as an isolated botanical extract or within conventional pharmaceutical formulations. No published studies currently investigate its incorporation into a region-specific neurodermal formulation system such as the SIRIAM Platform. Consequently, its inclusion reflects both established biological plausibility and the architectural design philosophy of the platform rather than established evidence for region-specific neurodermal application.

Ginkgo biloba functions as a common botanical ingredient of the Release Core.

Its architectural role is to complement the functional characteristics shared by Release-oriented formulations while remaining independent of regional anatomical differentiation.

Future pharmaceutical optimisation may refine extract selection and concentration according to platform development without altering its architectural position.